Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIS-BBB-05
- Development stage
- Preclinical
- Lead developer
- Fannin Innovation Studio
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FIS-BBB-05 is a preclinical-stage modified DNA aptamer (Raptamer) being developed by Raptamer Discovery Group, a portfolio company of Fannin Innovation Studio. The program is designed for blood-brain barrier (BBB) applications and brain delivery, aiming to facilitate the transport of therapeutic payloads across the BBB into the central nervous system. FIS-BBB-05 is currently in preclinical development, with evaluation progressing from in vitro studies to in vivo models.
Beyond the preview
Go deeper on FIS-BBB-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIS-BBB-05.